MMSI
Merit Medical Systems, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
90.72
▲ 0.45 (0.50%)
MARKET · —
Price
Open
90.09
Prev close
90.27
Day high
91.03
Day low
89.38
Volume
371.64K
Market cap
$5.42B
P/E (TTM)
37.36
52W range
59.74 – 94.75
Trailing performance
Returnvs SPY
1W
+0.02%
+1.4%
1M
+24.17%
+20.4%
3M
+42.67%
+39.6%
6M
+10.42%
-0.6%
YTD
+3.00%
-9.3%
1Y
+3.91%
-16.1%
3Y
+34.91%
-39.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$5.42B
Enterprise value$5.79B
Revenue (TTM)$1.58B
Gross profit$781.73M
EBITDA$338.94M
Net income$145.56M
EPS (TTM)$2.43
Free cash flow$173.90M
Total cash$448.70M
Total debt$820.12M
Book value / share$28.13
Shares outstanding59.71M
Float58.29M
Short % of float8.46%
Dividend yield—
Beta (5Y)0.48
Valuation & profitability ratios
Trailing P/E37.36
Forward P/E19.69
PEG ratio1.83
Price / sales—
Price / book3.23
EV / revenue3.67
EV / EBITDA17.09
Gross margin49.51%
Operating margin14.46%
Profit margin9.22%
Return on equity9.19%
Return on assets4.92%
Debt / equity48.82
Current ratio4.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.52B | $1.36B | $1.26B | $1.15B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $128.49M | $120.36M | $94.41M | $74.52M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $128.49M | $120.36M | $94.41M | $74.52M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.96 | 1.19 | +24.0% |
| Mar 2026 | 0.83 | 0.94 | +12.8% |
| Dec 2025 | 0.95 | 1.04 | +9.0% |
| Sep 2025 | 0.83 | 0.92 | +11.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.03 | 10 | $410.38M | +6.8% |
| Next quarter | 1.14 | 10 | $425.02M | +7.9% |
| Current year | 4.30 | 10 | $1.64B | +7.9% |
| Next year | 4.61 | 10 | $1.74B | +6.1% |
Analyst targets & ownership
Mean target$100.27
High target$114.00
Low target$83.00
Implied upside10.53%
Analyst count11
ConsensusBUY
Strong buy / Buy5 / 4
Hold2
Sell / Strong sell0 / 0
Held by insiders2.44%
Held by institutions108.21%
Institutions holding546
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+215.31K
Net buying
Buy transactions
23
241.75K shares
Sell transactions
2
26.45K shares
Net transactions
+25
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
1.46M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 4, 26 | PETERSON NEIL W Chief Operating Officer |
SELL | 21.45K | $1.82M | Direct |
| Jun 15, 26 | VOIGT MICHEL JAMES Officer |
STOCK | 65 | $0 | Direct |
| Jun 5, 26 | LLOYD BRIAN G Officer |
STOCK | 2.00K | $0 | Direct |
| May 20, 26 | GUNDERSON THOMAS JAMES Director |
CONVERSION | 21.25K | $1.11M | Direct |
| May 18, 26 | WARD SCOTT RAYMOND Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | CARPENTER LONNY J Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | MILLNER F ANN Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | GUNDERSON THOMAS JAMES Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | KAISER LAURA S. Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | WARD LYNNE N. Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | MCDONNELL MICHAEL R Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | EVANS STEPHEN C Director |
STOCK | 3.46K | $0 | Direct |
| May 18, 26 | PEREZ SILVIA Director |
STOCK | 3.46K | $0 | Direct |
| May 11, 26 | SMITH CHRISTIAN ADAM Officer |
BUY | 1.63K | $99.19K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARONSON MARTHA GOLDBERG |
Chief Executive Officer | 49.79K | Purchase |
CARPENTER LONNY J |
Director | 20.82K | Stock Award(Grant) |
GUNDERSON THOMAS JAMES |
Director | 60.74K | Conversion of Exercise of derivative security |
LAMPROPOULOS FRED P |
Officer and Director | 1.13M | Sale |
LLOYD BRIAN G |
Officer | 62.13K | Stock Gift |
MILLNER F ANN |
Director | 38.00K | Stock Award(Grant) |
PARRA RAUL JR. |
Chief Financial Officer | 61.54K | Purchase |
PETERSON NEIL W |
Chief Operating Officer | 25.55K | Sale |
SMITH CHRISTIAN ADAM |
Officer | — | Purchase |
VOIGT MICHEL JAMES |
Officer | 48.33K | Stock Gift |
Moving averages & technicals
SMA 10
90.53
+0.21% from price
SMA 20
87.21
+4.09% from price
SMA 50
77.32
+17.41% from price
SMA 100
71.40
+27.07% from price
SMA 200
76.48
+18.69% from price
EMA 12
89.18
+1.72% from price
EMA 26
85.00
+6.73% from price
EMA 50
79.89
+13.56% from price
RSI (14)
70.6
Overbought
MACD (12,26,9)
4.18
Hist -0.30
ATR (14)
2.05
2.26% of price
Realised vol 30D
27.5%
Annualised
Bollinger upper
96.02
20, 2σ
Bollinger lower
78.40
20, 2σ
50 / 200 cross
Golden
77.32 vs 76.48
Trend bias
Above 200
+18.69%
Risk profile
Beta vs SPY
0.50
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
27.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.3%
Peak to trough
Max drawdown 5Y
-45.3%
Peak to trough
ATR 14
2.05
2.26% of price
Beta (reported)
0.48
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.40
Call-heavy session
Put / call open interest
2.78
Positioning, not flow
Max pain
90.00
-0.9% from spot
ATM implied vol
46.1%
Nearest strike to spot
Skew (10% OTM)
-6.3%
Calls bid over puts
Call volume
20
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
95.00
19 contracts
Heaviest put OI
90.00
193 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
COO vs. MMSI: Which Stock Is the Better Value Option?
Zacks · 1d ago
Merit Medical Systems COO Neil Peterson to Transition to Senior Adviser Role
MT Newswires · 3d ago
Merit Medical Announces Global Operations Leadership Transition
GlobeNewswire · 3d ago
3 Overrated Stocks with Warning Signs
StockStory · 4d ago
Merit Medical Eyes Next Growth Plan as Margins, Portfolio Review Take Center Stage
MarketBeat · 7d ago
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum
MarketBeat · 7d ago
Merit Medical (MMSI) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
Merit Medical Systems Insider Sold Shares Worth $1,823,165, According to a Recent SEC Filing
MT Newswires · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.